HYFT

ImmunoPrecise Antibodies Ltd.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$70.53M
P/E Ratio
EPS
$-0.09
Beta
0.83
52W High
$3.25
52W Low
$0.99
50-Day MA
$1.49
200-Day MA
$1.60
Dividend Yield
Profit Margin
-43.60%
Forward P/E
PEG Ratio

About ImmunoPrecise Antibodies Ltd.

MindWalk Holdings Corp. The company is headquartered in Austin, Texas.

Official WebsiteUSAFY End: April

Fundamentals

Revenue (TTM)$28.08M
Gross Profit (TTM)$16.06M
EBITDA$-10.48M
Operating Margin-88.40%
Return on Equity-58.80%
Return on Assets-18.90%
Revenue/Share (TTM)$0.61
Book Value$0.23
Price-to-Book6.98
Price-to-Sales (TTM)2.51
EV/Revenue3.32
EV/EBITDA-4.68
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)52.40%
Shares Outstanding$46.71M
Float$45.37M
% Insiders9.02%
% Institutions9.99%

Historical Volatility

HV 10-Day
76.29%
HV 20-Day
63.34%
HV 30-Day
79.59%
HV 60-Day
90.06%
HV Rank
9.1%

Volatility is currently contracting

Analyst Ratings

Consensus ($4.33 target)
3
Buy

Latest News

MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has been added to the Russell 3000E Index, effective after the U.S. market close on June 26, 2026, as part of the FTSE Russell June 2026 semi-annual Russell US Indexes Reconstitution. Membership was reconfirmed in index data published June 29, 2026. The Russell 3000E Index is FTSE Russell's broadest measure of the U.S. equity market, covering up to the 4,000 of t.

Business Wire7/6/2026Neutral
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced the filing of European patent application No. EP26187897.9, directed to high-dimensional data structures for biological subsequences and property inference. The application is intended to protect the enriched biological representation architecture that underpins MindWalk's HYFT® Technology, its ReefIQ™ biological context layer, and its LensAI™ reasoning workflows. The fi.

Business Wire7/1/2026Neutral
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

VICTORIA, British Columbia--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, li.

Business Wire6/10/2026Neutral
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (Nasdaq: HYFT) today reported preclinical dengue data that support a computational prediction its HYFT® platform generated before any animal was immunized. HYFT® computationally identified a candidate pan-serotype structural target on the dengue virus. The subsequent immunization data support that prediction at the antibody-binding level: animals immunized with immunogens designed on the predicted target generated antibodies that cross-rea.

Business Wire6/2/2026Neutral
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The Platform draws on the same biological intelligence in.

Business Wire5/27/2026Neutral
The Biology Came First.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in antibody discovery work performed at MindWalk facilities. Ten of these programs are in active clinical trials, spanning Phase 1 through Phase 3 across oncology, immunology, neurology, and infectious disease. In every case, the clinical asset is wholly owned, advanced, and funded by the partner. MindWalk's co.

Business Wire5/18/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026